We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

37 hedge funds and large institutions have $11.6M invested in Albireo Pharma Inc in 2014 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

14% less funds holding

Funds holding: 43 → 37 (-6)

35% less capital invested

Capital invested by funds: $17.8M → $11.6M (-$6.2M)

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

67% less call options, than puts

Call options by funds: $38K | Put options by funds: $116K

Holders
37
Holders Change
-6
Holders Change %
-13.95%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
8
Closed
11
Calls
$38K
Puts
$116K
Net Calls
-$78K
Net Calls Change
+$256K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$762K
2
SM
Sabby Management
Florida
+$558K
3
Goldman Sachs
Goldman Sachs
New York
+$254K
4
Renaissance Technologies
Renaissance Technologies
New York
+$94.5K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$21.1K

Top Sellers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
-$1.07M
2
NI
Numeric Investors
Massachusetts
-$914K
3
SFM
Sphera Funds Management
Israel
-$775K
4
FNYS
First New York Securities
New York
-$666K
5
TC
TFS Capital
Pennsylvania
-$531K
Name Holding Trade Value Shares
Change 		Change in
Stake
U
26
UBS
Switzerland
$18K -$626 -9 -3%
BA
27
BlackRock Advisors
Delaware
$13K – – –
Ameriprise
28
Ameriprise
Minnesota
$8K +$8.69K +125 New
BIM
29
BlackRock Investment Management
Delaware
$7K +$8.06K +116 New
Morgan Stanley
30
Morgan Stanley
New York
$5K +$4.66K +67 +2,233%
Citigroup
31
Citigroup
New York
$3K -$4.17K -60 -55%
PMFA
32
Plante Moran Financial Advisors
Michigan
$3K +$3.41K +49 New
Bank of America
33
Bank of America
North Carolina
$2K +$70 +1 +3%
Creative Planning
34
Creative Planning
Kansas
$1K – – –
DADC
35
D.A. Davidson & Co
Montana
$1K – – –
MFS
36
MSI Financial Services
Massachusetts
$1K – – –
NI
37
Numeric Investors
Massachusetts
– -$914K -11,161 Closed
SFM
38
Sphera Funds Management
Israel
– -$775K -9,463 Closed
FNYS
39
First New York Securities
New York
– -$666K -8,133 Closed
DY
40
Dowling & Yahnke
California
– -$175K -2,135 Closed
Group One Trading
41
Group One Trading
Illinois
– -$103K -1,488 Closed
Two Sigma Investments
42
Two Sigma Investments
New York
– -$88K -1,078 Closed
Two Sigma Advisers
43
Two Sigma Advisers
New York
– -$54K -670 Closed
Millennium Management
44
Millennium Management
New York
– -$46K -557 Closed
Citadel Advisors
45
Citadel Advisors
Florida
– -$27K -333 Closed
AllianceBernstein
46
AllianceBernstein
Tennessee
– -$1K -15 Closed
TRCT
47
Tower Research Capital (TRC)
New York
– +$209 +3 New
1
2

ALBO Hedge Fund Activity: Q2 2014 in Review

37 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2014, worth a combined $11.6M — down 35% from $17.8M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ALBO and 5 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 9 added.

The largest buyer was Wellington Management Group, adding an estimated $762K. The largest seller was William Blair & Company, cutting an estimated $1.07M.

  • 37 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2014, down from 43 in Q1 2014.
  • Funds reported $11.6M of Albireo Pharma Inc stock for Q2 2014, down 35% quarter-over-quarter.
  • 5 funds opened new Albireo Pharma Inc positions in Q2 2014 and 11 closed out, a net change of -6 holders.
  • The largest Albireo Pharma Inc buyer in Q2 2014 was Wellington Management Group, an estimated $762K added.
  • The largest Albireo Pharma Inc seller in Q2 2014 was William Blair & Company, an estimated $1.07M sold.

Based on aggregated 13F filings for Q2 2014.